期刊
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
卷 14, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13223-018-0281-6
关键词
Atopic dermatitis; Diagnosis and management; Emollients; Skin care practices; Topical corticosteroids; Topical calcineurin inhibitors
资金
- AstraZeneca
- Boehringer Ingelheim
- CSL Behring Canada Inc.
- MEDA Pharmaceuticals Ltd.
- Merck Canada Inc.
- Pfizer Canada Inc.
- Shire Pharma Canada ULC
- Stallergenes Greer Canada
- Takeda Canada
- Teva Canada Innovation
- Aralez Tribute
- Pediapharm
Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations. Successful management of the disorder requires a multifaceted approach that involves education, optimal skin care practices, anti-inflammatory treatment with topical corticosteroids and/or topical calcineurin inhibitors, the management of pruritus, and the treatment of skin infections. Systemic immunosuppressive agents may also be used, but are generally reserved for severe flare-ups or more difficult-to-control disease. Topical corticosteroids are the first-line pharmacologic treatments for AD, and evidence suggests that these agents may also be beneficial for the prophylaxis of disease flare-ups. Although the prognosis for patients with AD is generally favourable, those patients with severe, widespread disease and concomitant atopic conditions, such as asthma and allergic rhinitis, are likely to experience poorer outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据